Brendan Heiden, MD, of Washington University School of Medicine, discusses data from a unique real-world cohort of nearly 1 million patients in the Veterans Health Administration; researchers evaluated whether tobacco smoking duration improves lung cancer risk prediction compared with tobacco pack-years (Abstract 8004).
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included in the Plenary Session.
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced breast cancer with emergent ESR1 mutations. Earlier reports from the trial showed improved progression-free survival with the SERD (Abstract LBA1007).
Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).
Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstract 7012).
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) significantly and relevantly improved long-term quality of life—at the cost of a higher risk of loss or replacement of expander or implant—compared to subpectoral IBBR (Abstract 504).
